**PBT-6, a Novel PI3KC2γ Inhibitor in Rheumatoid Arthritis**

Juyoung Kim\(^1\), Kyung Hee Jung\(^1\), Jaeho Yoo\(^2\), Jung Hee Park\(^1\), Hong Hua Yan\(^1\), Zhenghuan Fang\(^1\), Joo Han Lim\(^1\), Seong-Ryuul Kwon\(^1\), Myung Ku Kim\(^1\), Hyun-Ju Park\(^2\) and Soon-Sun Hong\(^1\)*

\(^1\)Department of Medicine, College of Medicine, Inha University, Incheon 22313, 
\(^2\)School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea

**Abstract**

Phosphoinositide 3-kinase (PI3K) is considered as a promising therapeutic target for rheumatoid arthritis (RA) because of its involvement in inflammatory processes. However, limited studies have reported the involvement of PI3KC2\(\gamma\) in RA, and the underlying mechanism remains largely unknown. Therefore, we investigated the role of PI3KC2\(\gamma\) as a novel therapeutic target for RA and the effect of its selective inhibitor, PBT-6. In this study, we observed that PI3KC2\(\gamma\) was markedly increased in the synovial fluid and tissue as well as the PBMCs of patients with RA. PBT-6, a novel PI3KC2\(\gamma\) inhibitor, decreased the cell growth of TNF-\(\alpha\)-mediated synovial fibroblasts and LPS-mediated macrophages. Furthermore, PBT-6 inhibited the PI3KC2\(\gamma\)/Akt signaling pathway in both synovial fibroblasts and macrophages. In addition, PBT-6 suppressed macrophage migration via CCL2 and osteoclastogenesis. In CIA mice, it significantly inhibited the progression and development of RA by decreasing arthritis scores and paw swelling. Three-dimensional micro-computed tomography confirmed that PBT-6 enhanced the joint structures in CIA mice. Taken together, our findings suggest that PI3KC2\(\gamma\) is a therapeutic target for RA, and PBT-6 could be developed as a novel PI3KC2\(\gamma\) inhibitor to target inflammatory diseases including RA.

**Key Words:** Rheumatoid arthritis, Collagen-induced arthritis, PI3KC2\(\gamma\), RANKL

**INTRODUCTION**

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder with a prevalence of about 1% in the general population. RA is characterized by chronic inflammation in joints associated with synovial hyperplasia and infiltration of inflammatory cells into the synovial tissue. RA consequently causes joint stiffness and the progressive destruction of the articular cartilage and bone, placing a heavy burden on the individual and the society (Pap and Korb-Pap, 2015). RA is presented with multiple manifestations of inflammation due to complex causes; thus, various immune cells are involved in the development of inflammation (Mclinnes and Schett, 2011). In particular, the increase in macrophages in the synovium is a prominent feature of inflammatory lesions (Udalova et al., 2016). The activation of these cells can lead to the production of cytokines and mediators responsible for inflammation. Recently, abatacept, tocilizumab, rituximab, anakinra, infliximab, and etanercept have been used for treating RA (Frisell et al., 2018). However, about 40% of RA patients do not respond to these therapeutics (Gillespie et al., 2012). Considering the limited efficacy and adverse effects of current therapies, there is a critical need for novel targets and therapeutics for RA treatment.

Phosphoinositide 3-kinase (PI3K)/Akt signaling is a major regulator of inflammatory processes; thus, it has been considered as a promising drug target for the treatment of inflammatory and autoimmune diseases (Camps et al., 2005). PI3Ks are lipid kinases that phosphorylate phosphoinositides at the 3'-OH position of the inositol ring, giving rise to PtdIns(3)P, PtdIns(3,4)P2, and PtdIns(3,4,5)P3 (Divecha and Irvine, 1995). PI3Ks have eight different isoforms in mammals, which are divided into three classes (class I, II, and III) depending on their sequence homology and substrate specificity (Vanhaesebroeck et al., 1997). Of these, class I PI3Ks have been the most commonly investigated. Class I PI3Ks phosphorylate PI 4,5-diphosphate to produce PI 3,4,5-triphosphate and can be further subdivided into class IA (PI3KC1\(\alpha\), PI3KC1\(\beta\), and PI3KC1\(\delta\) isofoms) and class IB (PI3KC1\(\gamma\) isoform, class I

---

**Open Access** [https://doi.org/10.4062/biomolther.2019.153](https://doi.org/10.4062/biomolther.2019.153)

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Received** Sep 18, 2019  **Revised** Oct 15, 2019  **Accepted** Oct 17, 2019  **Published Online** Nov 18, 2019

*Corresponding Author*  E-mail: hongs@inha.ac.kr  Tel: +82-32-890-3683, Fax: +82-32-890-2462

\(^*\)The first three authors contributed equally to this work.  **www.biomolther.org**
PI3Kγ (Pirola et al., 2001). Among these isoforms, PI3KC1δ and PI3KC1γ are emerging as novel therapeutic targets for treating inflammatory diseases (Rommel et al., 2007; Harris et al., 2009). Especially, PI3KC1γ is mainly expressed in hematopoietic cells, playing a critical role in chemokine signaling and the recruitment of immune cells including macrophages, neutrophils, and T cells (Li et al., 2000). The defective migration of macrophages to injured sites and reduced chemotactrant-induced neutrophil respiratory burst have been observed in PI3KC1γ knockout mice (Hirsch et al., 2000; Del Prete et al., 2004). Considering the role of PI3KC1γ in inflammation, it is a potential therapeutic target for various inflammatory diseases in RA (Kim et al., 2012; Boyle et al., 2014). Indeed, the blockade of PI3KC1γ in CIA mouse models has been reported to suppress inflammatory damage in RA mice. In addition, a PI3Kγ inhibitor was found to reduce the clinical severity of arthritis and neutrophil accumulation in RA mouse models (Camps et al., 2005). Thus far, the role and function of PI3KC1γ (class I PI3Kγ) in various inflammatory diseases including RA have been extensively studied; however, little is known about the involvement of PI3KC2γ (class II PI3Kγ) in inflammation and RA even though it has attracted attention as a potential drug target (Freitag et al., 2015).

In this study, we investigated the association between PI3KC2γ and RA by evaluating the expression of PI3KC2γ in the serum and synovium of patients with RA. To target PI3KC2γ, we developed a novel oral PI3KC2γ inhibitor, PBT-6 (chemical name: 6-(4-pyridinyl)-2-benzothiazolamine), and the potential therapeutic targets of PBT-6 were validated in in vitro and in vivo models of arthritis (CIA mice). Furthermore, the underlying anti-arthritic mechanism of PBT-6 was investigated in synovial fibroblasts and macrophages.

**MATERIALS AND METHODS**

**Chemicals and antibodies**

Primary antibodies against PI3KC2γ (Thermo Fisher Scientific, Rockford, IL, USA), p-AKT1, p-AKT2, p-mTOR, β-actin (Cell Signaling Technology, Danvers, MA, USA), RANKL (Abcam, Cambridge, MA, UK), and NFATc1 (Santa Cruz Biotechnology, Dallas, CA, USA) were purchased. RANKL and M-CSF were obtained from R&D Systems (Minneapolis, MN, USA). In addition, method of PI3K-6 synthesis was in detail described in supplementary method. In brief, the first step was the acetylation of NH2 under mild conditions with pyridine and acetic anhydride. In the second step, bromo benzothiazol and boronic acid were coupled via the Suzuki reaction using a phosphine ligand, base, and Pd catalyst. In the final step, it was hydrolyzed in NaOH solution. 6-(pyridin-4-yl)-benzo[d][1H]thiazol-2-amine: 1H NMR (400 MHz, DMSO): 8.58 (d, J=6, 2H-Ar), 8.18 (d, J=1.6, 1H-Ar), 7.70-7.66 (m, 5H), 7.42 (d, J=8, 1H-Ar).

**Kinase profiling**

The activity of PBT-6, at a concentration of 1 μM with an ATP concentration of 10 μM, was screened against PI3 kinases by Eurofins (https://www.eurofinsdiscoveryservices.com/) using the Eurofins Kinase Profiler Selectivity Testing Service.

**PI3KC2γ kinase assay**

The ADP-Glo Kinase Assay kit was obtained from Promega (Madison, WI, USA). In a 1.5 mL microcentrifuge tube, 25 μM of APT, 0.1 mg/mL of PI3K substrate, and various concentrations of PBT-6 (0.1-100 μM) were added and followed by 5 ng/μL of PI3KC2γ enzyme. After incubation for 40 min at 30°C, 10 μL of ADP-GloTM reagent was added. After incubation for 40 min at 30°C, 10 μL of kinase detection reagent was added and spun down. Finally, after transfer to a white plate, the luminescence was read.

**Cell culture**

MH7A cells were purchased from Riken Cell Bank (Tsukuba, Japan) and cultured in RPMI1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin. Raw 264.7 cells were purchased from the Korean Cell Line Bank and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin. FBS and all other reagents used for cell culture were purchased from Invitrogen (Carlsbad, CA, USA). The cultures were maintained at 37°C in an incubator with a controlled humidified atmosphere composed of 95% air and 5% CO2.

**Measurement of cell viability**

Cell viability was determined by MTT assay. In brief, the cells were seeded at a density of 8×10³ cells/well in 96-well plates followed by overnight incubation. On the following day, the medium was removed, and the cells were treated with an inducer [TNF-α (50 ng/mL) or LPS (1 μg/mL)] and various concentrations of PBT-6 (0.1-100 μM). After incubation for 72 h, 10% of MTT solution (2 mg/mL) was added to each well, and the cells were incubated for another 4 h at 37°C. The formazan crystals obtained were dissolved in DMSO (100 μL/well) with constant shaking for 5 min. The absorbance of the plate was then read with a microplate reader at 540 nm. Three replicate wells were evaluated for each analysis.

**Western blotting**

The cells were washed with DPBS before they were lysed in lysis buffer containing protease and phosphatase inhibitors. Equal amounts of proteins were separated by 8, 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. Protein transfer was confirmed using Ponceau S staining solution (Sigma-Aldrich, St. Louis, MO, USA). The blots were then immunostained with the appropriate primary antibodies (1:1000) followed by secondary antibodies (1:5000) conjugated to horseradish peroxidase. The primary antibodies specific to the target proteins were detected manually using an X-Ray film by enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ, UK).

**Enzyme-linked immunosorbent assay (ELISA)**

Informed consent was obtained from all of the patients, and the experimental protocol was approved by the Inha University Hospital Human Research Ethics Committee (INHAIUH IRB 2015-09-016-002). In addition, we confirm that all experiments were performed in accordance with relevant guidelines and regulations. Peripheral blood and synovial fluid were collected from healthy control volunteers (HC, n=8), osteoarthritis patients (OA, n=9), and RA patients (RA, n=9). ELISA kits were purchased from R&D Systems, and cytokine levels in the serum or synovial fluid were measured according to the

---

**Kim et al. Effect of PBT-6 in RA**

---
manufacturer’s instructions. In brief, each well was coated with 0.1 g of TNF-α, IL-1β, and IL-6 for 24 h and blocked with PBS containing 2% BSA for 1 h at room temperature. Then, serum or synovial fluid was added to each well and incubated for 24 h at 4°C. After washing the plate with PBS containing 0.1% Tween 20, biotinylated antibody was added to each well and reacted with streptavidin- horseradish peroxidase. After washing the plate, 3,3′,5,5′-tetramethylbenzidine solution was added for 20 min. The reaction was stopped by the addition of 1 N sulfuric acid, and the signal was read at 450 nm. For in vitro cytokine secretion assay, MH7A cells (5×10⁴) or Raw 264.7 cells (5×10⁶) were seeded in 12-well plates and incubated with 1 and 10 μM of PBT-6 for 6 h. Then, LPS or TNF-α was added for 24 h. The culture medium was harvested and used for cytokine measurements.

**PI3KC2γ siRNA transfection**

PI3KC2γ siRNA or negative control siRNA was purchased from Signal Chem (Richmond, BC, Canada). Cells (5×10⁵ cells for MH7A and Raw 294.7) were transfected with 100 pM/each well of either the PI3KC2γ siRNA or control siRNA using Lipofectamine 2000 (5 μL/well, Invitrogen) in Opti-MEM.
medium for 6 h. Cells were then re-suspended in complete media, incubated for 48 h and used for further experiments.

**In vivo CIA model**

All animal experiments were performed in accordance with the guidelines of the INHA Institutional Animal Care and Use Committee (INHA IACUC) of the Medical School of Inha University (approval ID: INHA 170718-501). Pathogen-free DBA/1 mice (male, 6 weeks, 20-22 g) were purchased from Orient Bio (Seoul, Korea). The mice were housed under specific pathogen-free conditions with a cycle of 12 h light/12 h dark, a temperature range of 22 ± 1°C and 55 ± 5% relative humidity. All mice were fed standard laboratory chow and water ad libitum and allowed to acclimatize in our facility for 1 week before any experiments started. For immunization, 200 μg of native bovine type II collagen (Chondrex Inc., Redmond, WA, USA) was mixed with an equal volume of Complete Freund’s Adjuvant (Chondrex) by vortexing for 15 min at room temperature. The DBA/1 mice were intradermally immunized in the basal region of the tail with 100 μL of the prepared mixture. On day 21, the mice were boosted with 200 μg of bovine type II collagen in 200 μg Incomplete Freund’s Adjuvant (Chondrex). The complete development of CIA was observed 14 days after booster injection. Mice with an arthritis score of 1 or/and 2 were selected and grouped; 20 experimental mice were evenly divided into three groups (group 1, normal control; group 2, vehicle; group 3, 10 mg/kg PBT-6). All mice (except normal control mice) were treated randomly via orally injected once a week for 40 days after the primary immunization. Paw swelling was scored by two independent observers. All four legs of the mice were evaluated and scored from 0 to 4 according to the following scale: (0, no signs of arthritis; 1, redness of the paw following scale: (0, no signs of arthritis; 1, redness of the paw or one digit; 2, slight swelling of the ankle or wrist with swelling of limited individual digits; 3, moderate swelling of the ankle or wrist; 4, severe swelling of the entire paw including the digits). Al=the sum of the limb joint swelling grade score (1 grade represented 1 point, the total was 16 points).

**Micro-CT imaging**

The mice were anaesthetized with mixture of ketamine (100 mg/kg) and xylazine (2%, 20 mg/kg). Their legs were then excised and fixed in 4% formalin for 2 days. The paws (from the tip of the toes to the end of the distal phalanx) obtained from the experimental mice were scanned, and the images were reconstructed into a three-dimensional structure by micro-CT (SkyScan 1172; Bruker, Kontich, Belgium) with a voxel size of 13.38 mm. The X-ray tube voltage was 59 kV, and the current was 167 mA with a 0.5 mm-thick aluminum filter. The exposure time was 1160 ms. X-ray projections were obtained at 0.450° intervals with a scanning angular rotation of 180°.

**Tartrate-resistant acid phosphatase (TRAP) staining assay**

Raw 264.7 cells were cultured in differentiation medium containing 100 ng/ml RANKL and 30 ng/ml M-CSF with varying concentrations of PBT-6 (1-10 μM) for 6 days. A TRAP staining kit (Sigma-Aldrich) was used to evaluate TRAP expression. TRAP* multinucleated cells that contained three or more nuclei were counted as osteoclasts by optical microscopy (Olympus, Tokyo, Japan), and Image Pro Plus (Media Cybernetics, Washington, MD, USA) was used to quantify the data.

**Transwell migration assay**

Macrophage migration assay was established using Transwell-24 units with polycarbonate filters that have a diameter of 6.5 mm and a pore size of 8.0 μm (Corning Costar, Cambridge, MA, USA) according to the manufacturer’s instructions. In brief, TNF-α-treated MH7A cells (with or without PBT-6 in growth medium) were cultured in 24-well flat bottom plates. Then, Raw 264.7 cells were starved for 3 h and added to the upper chambers of the Transwell inserts containing LPS in 2% FBS DMEM. A goat anti-mouse CCL2 neutralizing antibody (500 ng/mL) was used with the chemotaxis assay media to determine the biological specificity of the above chemokines produced by the cells to stimulate macrophage migration. After 48 h, the Raw 264.7 cells in the upper compartment were gently wiped away with a cotton swab to remove unmigrated cells, and migrated cells on the underside of the membranes in the Transwell unit were fixed with 20% methanol and stained with 0.2% crystal violet for 30 min. Migrated macrophages were quantified by counting 5 random spots for each sample.

**Immunohistochemistry**

Joint tissue samples obtained from CIA mice were decalciﬁed and ﬁxed in 10% buffered formaldehyde at 4°C overnight. They were embedded in paraffin, and sectioned. Immunostaining was performed on 8 mm sections of joint samples after deparaffinization. Antigen retrieval was performed by incubation with 0.2 mg/mL Proteinase K (Thermo Fisher Scientific, USA) was used to quantify the

| Kinase name POC | Compound Concentration (nM) |
|-----------------|----------------------------|
| EGFR (h)        | 102                        | 1000                      |
| FGFR1 (h)       | 133                        | 1000                      |
| IGF-1R (h)      | 101                        | 1000                      |
| MEK1 (h)        | 99                         | 1000                      |
| MEK2 (h)        | 101                        | 1000                      |
| mTOR (h)        | 86                         | 1000                      |
| PDGFRα (h)      | 106                        | 1000                      |
| PKBα (h)        | 101                        | 1000                      |
| PKBβ (h)        | 83                         | 1000                      |
| PKBγ (h)        | 108                        | 1000                      |
| P3 Kinase (p110α(E542K)/p85α) (h) | 87                  | 1000                      |
| P3 Kinase (p110α(H1047R)/p85α) (h) | 87                  | 1000                      |
| P3 Kinase (p110α(E545K)/p85α) (h) | 89                  | 1000                      |
| P3 Kinase (p110α/p85α) (h) | 95                        | 1000                      |
| P3 Kinase (p110α/p65α) (h) | 91                        | 1000                      |
| P3 Kinase (p110b/p85α) (h) | 89                        | 1000                      |
| P3 Kinase (p110d/p85α) (h) | 96                        | 1000                      |
| P3 Kinase (p120g) (h) | 66                         | 1000                      |
| P3KC2a (h)      | 102                        | 1000                      |
| P3KC2g (h)      | 0                          | 1000                      |

A panel of kinases was tested at 1 μM concentrations in a high-throughput binding assay. Only representative kinases are shown here. Lower percent of control (POC) values represent stronger hits. Values shown are the mean of duplicate measurements.
Grand Island, NY, USA) in PBS for 15 min at room temperature. After gentle washing twice with PBS, endogenous peroxidase was blocked using 0.3% H₂O₂ in distilled water for 15 min at room temperature. The tissue sections were washed with PBS, blocked with normal goat or horse serum (Vector Laboratories, Burlingame, CA, USA) for 1 h, and incubated at 4°C overnight in 1:50 dilutions of primary antibodies against PI3KC2γ and p-AKT2 (S474). The sections were then incubated with biotinylated secondary antibodies (1:100) for 1 h and visualized with an avidin-biotin-peroxidase complex solution using an ABC kit (Vector Laboratories). Subsequently, they were washed with PBS, developed with a diaminobenzidine tetrahydrochloride (DAB) substrate for 5 min, and counterstained with hematoxylin. At least 3 randomly selected fields for each section were examined at 200× magnification.

**Data and statistical analysis**

The data and statistical analysis in this study comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology (Curtis et al., 2015). All the images of western blots and immunohistochemistry staining were quantified using Image J 1.41. All experimental data are presented as mean ± SD, and each experiment was performed a minimum of three times. All group data subjected to statistical analysis in the present research have a minimum of n=5 individuals per group or independent samples according to the power analysis in pharmacology (Curtis et al., 2015). Statistical analyses were evaluated using GraphPad Prism 6.0 software (RRID: SCR_002798, GraphPad, La Jolla, CA, USA). Two groups were compared by analyzed by Student’s t-test. Three or more different groups were evaluated by one-way ANOVA. A p value of 0.05 or less was regarded as statistically significant.

**RESULTS**

**PI3KC2γ expression in the synovial fluid, synovial tissue, and peripheral blood mononuclear cells (PBMCs) of RA patients**

First, we examined the expression of PI3KC2γ and pro-inflammatory cytokines in the synovial fluid. Analysis of the synovial fluid by ELISA revealed that PI3KC2γ and cytokines such as IL-6, IL-1β, and TNF-α were significantly increased in RA patients compared with osteoarthritis (OA) patients (Fig. 1A). In addition, we evaluated the expression of PI3KC2γ in synovial tissue with histopathologic changes such as noticeable synovial endothelial hyperplasia, granular formation, fibroblast proliferation, vascular proliferation, and severe inflammatory cell infiltration. The expression of PI3KC2γ was markedly increased in the cells of the synovial lining layers and inflammatory infiltrates in the synovial tissue of RA patients compared with OA patients (Fig. 1B). Moreover, the protein level of PI3KC2γ was increased in RA PBMCs compared with healthy control PBMCs (Fig. 1C, 1D). These results demonstrated that PI3KC2γ was increased in the synovial fluid, synovial tissue, and PBMCs of RA patients, indicating that PI3KC2γ is an important regulator of the inflammatory response in RA.

**Discovery of PBT-6, a novel PI3KC2γ inhibitor**

The chemical structure of a novel PI3KC2γ inhibitor, PBT-6, is shown in Fig. 2A. When PBT-6 was subjected to kinase

![A](image1.png)  ![B](image2.png)  ![C](image3.png)  ![D](image4.png)

**Fig. 3.** Effect of PBT-6 in TNF-α-induced MH7A cells. (A) TNF-α-mediated MH7A cells were treated with PBT-6 at the indicated concentration for 72 h, and MTT assays were performed. (B) MH7A cells were treated with PBT-6 (10 μM) for 24 h after stimulation by TNF-α (50 ng/mL). TUNEL assay were performed. (C) MH7A cells pretreated for 6 h with PBT-6 were stimulated with TNF-α for 24 h. The culture medium was then collected, and the concentration of IL-6 was measured. (D) Cells were pretreated with the PI3KC2γ inhibitor PBT-6 (1 and 10 μM) for 6 h and stimulated with TNF-α for 30 min before cell lysis.

https://doi.org/10.4062/biomolther.2019.153
selectivity profiling with a panel of PI3 kinases at 1 μM (Table 1). PBT-6 selectively inhibited PI3KC2γ activity. Next, a homogeneous time-resolved fluorescence (HTRF) kinase assay was performed to measure the binding affinity of PBT-6 to PI3KC2γ. As shown in Fig. 2B, PBT-6 effectively inhibited PI3KC2γ activity, yielding a Kd value of 0.826 μM. Our results indicated that PBT-6 is sufficiently specific to PI3KC2γ.

Effect of PBT-6 on TNF-α-induced MH7A synovial fibroblasts

Inflammatory cytokines have been identified as key mediators in the pathogenesis of RA (Brennan et al., 1998). Among these cytokines, TNF-α is considered as an essential cytokine for inducing the generation of other inflammatory cytokines in RA (Mukaida et al., 1990). In addition, IL-6 is a master cytokine that is involved in the RA cytokine cascade. Successful anti-cytokine therapies have demonstrated their critical roles in the pathogenesis of RA (Nishimoto et al., 2000; Min et al., 2004). Therefore, we assessed cell viability and measured the IL-6 level in TNF-α-induced synovial fibroblasts (MH7A). When MH7A cells were treated with PBT-6, PBT-6 similarly induced about 40% cell death at 20-100 μM in a dose-independent manner (without TNF-α). However, PBT-6 increased cell death of TNF-α-induced synovial fibroblasts in a dose-dependent manner. In particular, PBT-6 treatment inhibited cell growth by 40-50% at a concentration of 10 μM (Fig. 3A). Cell death of PBT-6 was confirmed by TUNEL assay (Fig. 3B). In addition, PBT-6 significantly decreased the IL-6 level in MH7A cells (Fig. 3C). We also determined whether PBT-6 could inhibit the PI3K/AKT pathway in MH7A cells. As expected, PBT-6 significantly inhibited the phosphorylation of AKT and mTOR, which are key molecules in the PI3K/AKT pathway (Fig. 3D).

Effect of PBT-6 on LPS-activated Raw 264.7 macrophages

RA is characterized by a massive infiltration of a variety of inflammatory cells including synovial macrophages (Iwamoto et al., 2008). Macrophages are one of the most abundant cell types in the RA synovia and can critically drive the progression of RA (Reddy and Rao, 1976; Burmester et al., 1997). Accordingly, we investigated whether PBT-6 could affect the cell viability of LPS-activated Raw 264.7 macrophages and the secretion of cytokines such as TNF-α and IL-6. When Raw 264.7 macrophages were treated with PBT-6, PBT-6 induced little increase cell death (without TNF-α). However, PBT-6 increased cell death of LPS-activated macrophages in a dose-dependent manner (Fig. 4A), and the secretion of IL-6 and TNF-α was markedly decreased by PBT-6 in LPS-activated Raw 264.7 macrophages (Fig. 4B, 4C). Moreover, PBT-6 significantly inhibited the phosphorylation of AKT and mTOR, indicating that PBT-6 inhibited the secretion of inflammatory cytokines by blocking PI3K/AKT/mTOR signaling.

Effect of PBT-6 on PI3KC2γ knockdown cells

To better characterize the contribution of PI3KC2γ-mediated PI3K/AKT signaling and to confirm PI3KC2γ targeting of PBT-6, we investigated the changes of PI3K/AKT signaling after silencing PI3KC2γ gene in MH7A synovial fibroblast and Raw 264.7 macrophage cells. As shown in Fig. 5A, when PI3KC2γ gene was silenced, expression of p-AKT1, p-AKT2, and pan-AKT was decreased in the both cells. Given that expression of AKT1 and AKT2 was similarly low in synovial fibroblast, PI3KC2γ appears to activate PI3K/AKT signaling by affecting both AKT1 and AKT2. Next, we investigated whether PBT-6 is effective in PI3KC2γ-knockdown cells. When PI3KC2γ-silenced MH7A cells were treated with PBT-6, it did not de-

Fig. 4. Effect of PBT-6 in LPS-induced Raw 264.7 macrophages. (A) LPS-mediated Raw 264.7 cells were treated with PBT-6 at the indicated concentration for 72 h, and MTT assays were performed. (B, C) Raw 264.7 cells pretreated for 6 h with PBT-6 were stimulated with LPS for 24 h. The culture medium was then collected, and the concentrations of IL-6 and TNF-α were measured. (D) Cells were pretreated with the PI3KC2γ inhibitor PBT-6 (1 and 10 μM) for 6 h and stimulated with LPS for 30 min before cell lysis. *p<0.05, **p<0.01, ***p<0.001 versus LPS-treated cells.
crease cell viability compared to siControl cells (Fig. 5B). Also, when PI3KC2γ was silenced, AKT/mTOR pathway was decreased. However, when this signaling was activated by TNF-α or LPS, PBT-6 did not suppress AKT/mTOR pathway in PI3KC2γ-knockdown cells. From these results, we suggest that PBT-6 shows effects by inhibiting AKT/mTOR signaling via PI3KC2γ binding (Fig. 5C).

Effect of PBT-6 on migration of macrophages and the osteoclastogenesis

As macrophages are a major source of cytokines and chemokines, which control the migration and infiltration of monocytes/macrophages into the inflamed synovium (Burmeister et al., 1997), we investigated whether PBT-6 could inhibit macrophage migration to synovial fibroblasts with chemotraction by Transwell chamber assay. The migration of activated macrophages was suppressed by PBT-6 (10 μM) treatment in the conditioned medium of TNF-α-induced synovial fibroblasts (bottom plate) (Fig. 6A). CCL2 is a key regulator in monocyte migration such as macrophage and the inflammatory response during RA pathogenesis (Koch et al., 1992). Thus, we identified whether PBT-6 could inhibit macrophage migration via CCL2. For this experiment, we used CCL2 neutralizing antibody. An *in vitro* chemotaxis assay revealed that macrophage migration in response to synovial fibroblast was attenuated by incubation with an anti-CCL2 neutralizing antibody (Fig. 6B). Also, PBT-6 inhibited macrophage migration to synovial fibroblasts (Fig. 6A). However, PBT-6 did not inhibit macrophage migration after treatment of CCL2 neutralizing antibody (Fig. 6B). These results imply that inhibition of macrophage migration by PBT-6 may be blocked via regulation of CCL2 inhibition.

Inflammation is known to increase osteoclastogenesis in RA. In addition, cytokines such as TNF-α and IL-6 (which are osteoclastogenic) can promote osteoclastic bone resorption (Weitzmann et al., 2000). Also, the migrated synovial macrophage highly induced osteoclast differentiation. Given that PBT-6 decreased the production of TNF-α and IL6 in macrophages and synovial fibroblasts and decreased macrophage migration to synovial fibroblasts, we hypothesized that PBT-6 could inhibit osteoclastogenesis. To determine the effects of PBT-6 on osteoclastogenesis, the formation of osteoclast cells from Raw 264.7 macrophages was induced by the addition of RANKL (100 ng/mL). Cells in the control group were successfully differentiated into mature TRAP-positive multinucleated osteoclasts, and PBT-6 effectively reduced the formation of TRAP-positive osteoclasts (Fig. 6C, ***p<0.01). The RANKL receptor (RANK) to nuclear factor of activated T cells c1 (NFATc1) is known as the transcription factor most strongly induced by RANKL stimulation in the early phase of differentiation into osteoclasts, which regulates several genes required for osteoclastic differentiation (Asagiri et al., 2005). As shown in Fig. 6D, a significant increase in NFATc1 expression was observed in RANKL-stimulated Raw 264.7 cells, which was inhibited by PBT-6.

PBT-6 attenuates arthritis severity in mice with CIA

Considering the *in vitro* findings, the therapeutic effect of PBT-6 was evaluated in mice with CIA. As shown in Fig. 7A, PBT-6 attenuated the swelling, erythema, and joint rigidity of the paws of mice with CIA. In addition, arthritis scores were significantly lower in the PBT-6-treated group (oral injection of 10 mg/kg PBT-6) than in the vehicle-treated group (oral injection of 0.5% methyl cellulose) (Fig. 7B). Furthermore, paw thickness was measured to analyze the beneficial effect of PBT-6; the results were correlated with arthritis scores (Fig. 7C). Serum cytokine analysis demonstrated that TNF-α and IL-6 were significantly lower in the PBT-6-treated group than in the vehicle-treated group (Fig. 7D). Histopathologic evaluation revealed severe synovial inflammation, synovial hyperplasia, cartilage damage, pannus formation, and bone erosion in mice with CIA. In contrast, the ankle joints in the PBT-6-treated group showed great improvements (Fig. 7E). Consistently, histological scores revealed that synovial inflammation, cartilage destruction, and bone destruction were significantly attenuated by PBT-6 treatment in mice with CIA (Fig. 7F). Furthermore, PI3KC2γ and p-AKT2 were highly expressed in inflamed cells around the joints of CIA mice, but PBT-6 treatment inhibited their expression (Fig. 7G). When we analyzed bone changes by three-dimensional micro-computed tomography, characteristic changes such as articular destruction, joint displacement, and irregular bone proliferation were observed in mice with CIA, and PBT-6 treatment alleviated bone destruction and increased bone volume, bone mineral density, and trabecular thickness (Fig. 8).
**Fig. 6.** Effect of PBT-6 on macrophage migration and osteoclastogenesis. (A) Raw 264.7 cell migration was assayed using 24-well Transwell inserts. MH7A synovial fibroblast cells became inflammation condition by TNF-α (100 ng/mL) treatment for 24 h. After collection of supernatants of MH7A cells, CM was added to lower chambers of the Transwell and PBT-6 (10 μM) was treated into CM. Then, Raw 264.7 cells were starved for 3 h and added to the upper chambers of the Transwell inserts containing 1 μg/mL LPS for 48 h in 2% FBS DMEM (**p<0.01 versus LPS-treated cells). (B) CM of synovial fibroblast MH7A cells was added to lower chambers of the Transwell and PBT-6 (10 μM) was treated into CM. Then, Raw 264.7 cells were starved for 3 h and added to the upper chambers of the Transwell inserts containing 1 μg/mL LPS for 48 h (**p<0.001). (C) The osteoclastogenesis of Raw 264.7 cells was induced by RANKL (100 ng/mL) and M-CSF (30 ng/mL) in the presence or absence of PBT-6 for 6 days. Multinucleated osteoclasts were counted after TRAP staining. Data represent the mean ± SD of three independent experiments (**p<0.001 versus control). (D) Raw 264.7 cells were pretreated with PBT-6 (1 and 10 μM) for 1 h and treated with RANKL (100 ng/mL) and M-CSF (30 ng/mL) in the presence or absence of PBT-6 for 24 h. NFArC1 and RANKL were detected with specific antibodies.

**DISCUSSION**

PI3Kγ has been reported to be involved in immune response activation and inflammation in RA. However, little is known about the involvement of PI3KC2γ in RA. In the present study, we demonstrate for the first time the up-regulation of PI3KC2γ in patients with RA and its association with inflammation and disease activity. The novel findings in our study indicate that PI3KC2γ could be a therapeutic target for RA and that PBT-6 (a PI3KC2γ inhibitor) could suppress arthritis progression in vitro and in vivo.

PI3Ks are interesting targets for the modulation of inflammatory diseases (Wetzker and Rommel, 2004), which are divided into class I, II, and III (Yu et al., 1998). The PI3KC1α and C1γ isoforms regulate a variety of cell functions including survival and proliferation, whereas the PI3KC1β and C1γ isoforms regulate immune responses (Katso et al., 2001). On the other hand, class II PI3Ks are composed of three isoforms, PI3KC2α, PI3KC2β, and PI3KC2γ (Wymann and Pirola, 1998; Foster et al., 2003). Among these isoforms, PI3KC2γ has a much more restricted tissue distribution than PI3KC2α and PI3KC2β, being generally localized in exocrine glands. High levels of PI3KC2γ are found in the liver (specifically in the hepatic parenchyma), breast, prostate, and salivary gland (Ho et al., 1997). A previous study on PI3KC2γ found that its expression is increased following partial hepatectomy, suggesting that PI3KC2γ may play a role in the maturation of hepatic cells (Lloyd and Deakin, 1975). In our study, the high expression of PI3KC2γ was confirmed in the liver, and there was no difference in its expression between RA and normal livers. However, the levels of PI3KC2γ in the synovial tissue and fluid of RA patients were significantly increased, indicating that PI3KC2γ may be a possible exacerbating factor of RA.

In contrast to class I PI3Ks, there are limited studies on isoform-specific inhibitors for class II PI3Ks including PI3KC2γ. Moreover, class II PI3Ks respond poorly to class I PI3K inhibi-
tors, and this has hindered the functional studies of this class of PI3K (O’Farrell et al., 2013). Given that PI3KC2γ was significantly increased in the synovial tissue and fluid of RA patients in our study, we hypothesized that the pharmacological blockade of PI3KC2γ might offer an innovative rationale-based therapeutic strategy for RA. Therefore, we developed PBT-6, a potent and isoform-selective PI3KC2γ inhibitor for RA treatment, and evaluated its effects. In the present study, we demonstrated that PBT-6 effectively ameliorated arthritis in mice with CIA. Histological analysis and micro-CT further confirmed that synovial inflammation, cartilage destruction, pannus formation, and bone destruction were significantly attenuated by PBT-6 treatment. In CIA mice, various cytokines, especially pro-inflammatory cytokines, play crucial roles in activating immune and inflammatory cells, which would favor the induction of autoimmunity, chronic inflammation, and subsequent joint destruction (McInnes and Schett, 2007). Our results show that treatment with PBT-6 significantly suppressed the systemic levels of pro-inflammatory cytokines such as TNF-α and IL-6 in vitro and in vivo.

In RA, synovial fibroblasts are a key component of the invasive rheumatoid synovium and play an important role in

https://doi.org/10.4062/biomolther.2019.153
the initiation and perpetuation of destructive joint inflammation (Huber et al., 2006; Bottini and Firestein, 2013). TNF-α is a predominant pro-inflammatory cytokine associated with RA and can stimulate the proliferation of synovial fibroblasts and increase the production of inflammatory mediators (Kapoor et al., 2011). In addition, IL-6 and IL-1β are downstream mediators of TNF-α, which together play a critical role in mediating synovitis and joint destruction in RA (Zheng et al., 2014). Therefore, TNF-α has been widely used to mimic arthritis in vitro studies (Rosengren et al., 2012; Jia et al., 2015). To further explore the possible pharmacological mechanism of PBT-6 in RA treatment, we investigated the effects of PBT-6 in TNF-α-induced human synovial fibroblasts (MH7A). The results showed that PBT-6 increased the cell death of TNF-α-induced human synovial fibroblasts and inhibited the level of IL-6. A recent study reported that PI3KC2γ could selectively control endosomal AKT2 activation on insulin signaling in liver (Braccini et al., 2015); thus, we investigated whether PBT-6 could inhibit the expression of AKT2 as well as AKT1 and mTOR (its downstream target) in synovial fibroblasts. PBT-6 effectively inhibited the PI3K signaling pathway activated by TNF-α via the suppression of the expression of AKT1, AKT2, and mTOR (its downstream target). Indeed, when PI3KC2γ gene was silenced, activation of both AKT1 and AKT2 was decreased in synovial cells. PI3KC2γ appears to activate of PI3K/AKT signaling by affecting both AKT1 and AKT2. When PI3KC2γ gene was silenced, the decrease of p-AKT expression by PBT-6 did not observed in TNF-α-induced synovial fibroblast. Collectively, we suggest that PBT-6 could inhibit PI3K/AKT signaling by targeting PI3KC2γ, thereby reducing the inflammatory response in synovial fibroblasts.

In addition to synovial fibroblasts, our study revealed that PBT-6 affected the activation and migration of macrophages. In RA, macrophages are the key effector cells in the acute and chronic phases by secreting pro-inflammatory cytokines and mediators that drive the infiltration of immune cells, cartilage damage, and bone destruction (Clavel et al., 2016). The number of synovial macrophages is positively correlated with disease severity such as the degree of joint damage (Mulherin et al., 1996). A change in synovial macrophages is a sensitive biomarker of the response to anti-rheumatic treatment in patients with RA (Haringman et al., 2005). In addition, emerging evidence suggests that the cell death of activated macrophages is an important mechanism for controlling inflammation (Tabas, 2010). In our study, PBT-6 increased the cell death of activated macrophages and further inhibited macrophage migration to synovial fibroblasts and TNF-α release, resulting in the reduction of inflammation in RA. Additionally, as CCL2 is one of the key factors involved in the initiation of inflammation, which triggers chemotaxis and migration of monocytes to inflammatory lesions, we identified whether PBT-6 inhibited macrophage migration via CCL2. Interestingly, when CCL2 was neutralized by its antibody, PBT-6 did not inhibit macrophage migration. These results imply that inhibition of macrophage migration by PBT-6 is blocked via regulation of CCL2.

Until now, little is known about the role of PI3KC2γ in inflammation. Only, Rozyczka et al. have reported that PI3KC2γ may be involved in immune cells signaling such as iCOS-iCOSL signaling and natural killing cells signaling from genomic sequencing data (Rasmussen et al., 2012). Also, Yu et al. (2010) have reported that knockdown of PI3KC2γ suppressed the activated chemotaxis in leukemia cells. Considering our results for the role of PI3KC2γ in RA, the PBT6, a PI3KC2γ inhibitor might suppress macrophage activation and its migration to synovial fibroblast via CCL2. From our results, we suggest that PBT-6 may be effectively involved in immune cells response such as macrophage via regulation of PI3KC2γ in inflammatory condition of RA.

Osteoclasts are multinucleated giant cells with the capacity to resorb mineralized tissues. They are derived from hematopoietic progenitors of the monocyte-macrophage lineage (Udagawa, 2003). Among osteoclastogenic factors, RANK is expressed on the surface of hematopoietic osteoclast progenitors that belong to the monocyte/macrophage lineage, thereby altering the RANK/RANKL/OPG system, which is the final regulator of bone resorption (Takayanagi et al., 2000; Hoftbauer and Heufelder, 2001; Romas et al., 2002). In arthritis, osteoclast precursors that express RANK recognize RANKL and differentiate into osteoclasts (Jones et al., 2002). In addition, TNF-α and IL-6 are representative osteoclastogenic cytokines that promote bone resorption by osteoclasts (Weitzmann et al., 2000). In particular, these cytokines can increase osteoclast function in cooperation with RANKL (Vitale and Ribeiro Fde, 2007). Recently, TNF-α and IL-6 have been reported to synergistically induce osteoclast-like cells and increase bone resorption activity (Yokota et al., 2014). In this study, as PBT-6 reduced the levels of TNF-α and IL-6 and the migration and activation of macrophages, we investigated whether PBT-6 could inhibit osteoclastogenesis. PBT-6 significantly inhibited the osteoclastic differentiation of RANKL-induced macrophages. Moreover, it decreased the expression of RANKL-induced osteoclastogenic marker genes such as TRAP and NFATc, thus demonstrating its anti-osteoclastogenic capacity. This effect was confirmed by micro-CT showing that PBT-6 significantly attenuated cartilage and bone destruction in mice with CIA. Based on the results, the anti-osteoclastogenic effect of PBT-6 may be attributed to the regulation of RANKL/RANK signaling by suppressing cytokines such as TNF-α and IL-6 with a protective mechanism against joint inflammation and bone destruction.

In conclusion, our data demonstrate that PI3KC2γ could be a therapeutic target for RA, which was significantly increased in the synovial fluid and tissue of RA patients. PBT-6, a selective PI3KC2γ inhibitor, improved RA symptoms and severity in vivo and in vitro by inhibiting osteoclastogenesis and cytokine production via the suppression of macrophage activation and migration. These results suggest that PBT-6 may exert a beneficial effect as a novel PI3KC2γ inhibitor in the treatment of RA.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

ACKNOWLEDGMENTS

This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government (MSIT) (No. 2019M3E5D1A02095361) and Inha University Grant, Korea.
Pap, T. and Korb-Pap, A. (2015) Cartilage damage in osteoarthritis and rheumatoid arthritis--two unequal siblings. *Nat. Rev. Rheumatol.* 11, 606-615.

Pirola, L., Zvelebil, M. J., Bulgarelli-Leva, G., Van Obberghen, E., Waterfield, M. D. and Wymann, M. P. (2001) Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha). Functions of lipid kinase-deficient PI3Kalpha in signaling. *J. Biol. Chem.* 276, 21544-21554.

Rasmussen, A. L., Wang, I. M., Shuhart, M. C., Proll, S. C., He, Y., Cristescu, R., Roberts, C., Carter, V. S., Williams, C. M., Diamond, D. L., Bryan, J. T., Ulrich, R., Korth, M. J., Thomassen, L. V. and Katze, M. G. (2012) Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesis. *Virology* 430, 43-52.

Reddy, V. A. and Rao, N. A. (1976) Dihydrofolate reductase from soybean seedlings. Characterization of the enzyme purified by affinity chromatograpy. *Arch. Biochem. Biophys.* 174, 675-683.

Romas, E., Gillespie, M. T. and Martin, T. J. (2002) Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. *Bone* 30, 340-346.

Rommel, C., Camps, M. and Ji, H. (2007) PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? *Nat. Rev. Immunol.* 7, 191-201.

Rosengren, S., Corr, M., Firestein, G. S. and Boyle, D. L. (2012) The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. *Ann. Rheum. Dis.* 71, 440-447.

Tabas, I. (2010) Macrophage death and defective inflammation resolution in atherosclerosis. *Nat. Rev. Immunol.* 10, 36-46.

Takayanagi, H., Iizuka, H., Juji, T., Nakagawa, T., Yamamoto, A., Miyazaki, T., Koshihara, Y., Oda, H., Nakamura, K. and Tanaka, S. (2000) Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. *Arthritis Rheum.* 43, 259-269.

Udagawa, N. (2003) The mechanism of osteoclast differentiation from macrophages: possible roles of T lymphocytes in osteoclastogenesis. *J. Bone Miner. Metab.* 21, 337-343.

Udalova, I. A., Mantovani, A. and Feldmann, M. (2016) Macrophage heterogeneity in the context of rheumatoid arthritis. *Nat. Rev. Rheumatol.* 12, 472-485.

Vanhaesebroeck, B., Leevers, S. J., Panayotou, G. and Waterfield, M. D. (1997) Phosphoinositide 3-kinases: a conserved family of signal transducers. *Trends Biochem. Sci.* 22, 267-272.

Vitale, R. F. and Ribeiro Fde, A. (2007) The role of tumor necrosis factor-alpha (TNF-alpha) in bone resorption present in middle ear cholesteatoma. *Braz. J. Otorhinolaryngol.* 73, 117-121.

Weitzmann, M. N., Cenci, S., Rifas, L., Brown, C. and Pacitti, R. (2000) Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. *Blood* 96, 1873-1878.

Wetzker, R. and Rommel, C. (2004) Phosphoinositide 3-kinases as targets for therapeutic intervention. *Curr. Pharm. Des.* 10, 1915-1922.

Wymann, M. P. and Pirola, L. (1998) Structure and function of phosphoinositide 3-kinases. *Biochim. Biophys. Acta* 1436, 127-150.

Wetzker, R. and Rommel, C. (2004) Phosphoinositide 3-kinases as targets for therapeutic intervention. *Curr. Pharm. Des.* 10, 1915-1922.

Yu, J., Wjasow, C. and Backer, J. M. (1998) Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase 3'-kinase. *Biochim. Biophys. Acta* 1436, 267-272.

Yu, W., Sun, X., Tang, H., Tao, Y. and Dai, Z. (2010) Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells. *Leuk. Lymphoma* 51, 1098-1107.

Zheng, Y., Sun, L., Jiang, T., Zhang, D., He, D. and Nie, H. (2014) TNF alpha promotes Th17 cell differentiation through IL-6 and IL-1beta produced by monocytes in rheumatoid arthritis. *J. Immunol. Res.* 2014, 385352.